Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 2/20 | 0.40 |
| ▸ | F3 | P13726 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170865 | 0.91 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL945677 | 0.91 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL251555 | 0.86 | CNR1 (0.46) | ALDH1A1CNR1CNR2LPAR2LPAR3 | |
| SCHEMBL251553 | 0.86 | CNR1 (0.46) | ALDH1A1CNR1CNR2LPAR2LPAR3 | |
| SCHEMBL16902073 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2F7F3 | |
| SCHEMBL931446 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2F7F3 | |
| SCHEMBL1921025 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL19617102 | 0.77 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14841814 | 0.77 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15930623 | 0.76 | ALDH1A1 (0.49) | ALDH1A1CNR1CNR2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2010 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | claimed |
| EP-4387657-A1 | LIPID NANOPARTICLE FORMULATIONS | Monash University (AU) | 2024-06-26 | — | — | EP | claimed |
| WO-2024119017-A1 | SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | claimed |
| US-20240175012-A1 | GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO | UNIV BRITISH COLUMBIA (CA) | 2024-05-30 | — | — | US | claimed |
| US-20240175024-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC. | 2024-05-30 | — | — | US | claimed |
| WO-2024095213-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS | INCISIVE GENETICS, INC. (CA) | 2024-05-10 | — | — | WO | claimed |
| EP-4281562-A1 | GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO | The University of British Columbia (CA) | 2023-11-29 | — | — | EP | claimed |
| US-11827883-B2 | Dosages and methods for delivering lipid formulated nucleic acid molecules | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | claimed |
| WO-2023218420-A1 | MRNA COMPOSITIONS FOR INDUCING LATENT HIV-1 REVERSAL | Janssen Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | WO | claimed |
| WO-2023166099-A1 | RNA LIPID NANOPARTICLES (LNPs) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE POLYMER | BioNTech SE (DE) | 2023-09-07 | — | — | WO | claimed |
| EP-1766035-A1 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2007-03-28 | — | — | EP | claimed |
| WO-2006074546-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-07-20 | — | — | WO | claimed |
| US-20060134189-A1 | siRNA silencing of apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2006-06-22 | — | — | US | claimed |
| US-20060083780-A1 | Cationic lipids and methods of use | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-04-20 | — | — | US | claimed |
| US-20060051405-A1 | Compositions for the delivery of therapeutic agents and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-03-09 | — | — | US | claimed |
| WO-2006007712-A1 | METHODS COMPRISING POLYETHYLENE GLYCOL-LIPID CONJUGATES FOR DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-26 | — | — | WO | claimed |
| US-20060008910-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTIES, INC. (CA) | 2006-01-12 | — | — | US | claimed |
| WO-2006002538-A1 | IMMUNOSTIMULATORY SIRNA MOLECULES AND USES THEREFOR | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-12 | — | — | WO | claimed |
| WO-2005121348-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | claimed |
| WO-2005120152-A2 | CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | claimed |